Inactive Instrument

Other languages Carbylan Therapeutics Inc Nasdaq

Equities

US1413841073

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

KalVista Pharmaceuticals, Inc. Presents Data At Eastern Allergy Conference 2024 and the Japanese Dermatological Association 2024	Jun. 06
Kalvista Pharmaceuticals Presents Data on Persisting Unmet Needs in Hereditary Angioedema At the European Academy of Allergy and Clinical Immunology Congress 2024	Jun. 03
Sector Update: Health Care Stocks Higher Late Afternoon	May. 31
Sector Update: Health Care	May. 31
KalVista Prospective Treatment for Swelling Disorder Meets Objectives -- Shares Rise	May. 31
Kalvista Pharmaceuticals Announces New England Journal of Medicine Publishes Oral Sebetralstat Phase 3 Data Demonstrating Its Potential to Transform the Treatment Landscape for People with Hereditary Angioedema	May. 31
Kalvista Pharmaceuticals Insider Sold Shares Worth $258,337, According to a Recent SEC Filing	May. 21
Kalvista Pharmaceuticals, Inc. Appoints William C. Fairey to the Board of Directors	Apr. 22
KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas	Mar. 18
KalVista Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024	Mar. 11
KalVista Pharmaceuticals, Inc. to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas	Mar. 08
KalVista Pharmaceuticals Names Benjamin Palleiko as CEO	Mar. 07
KalVista Pharmaceuticals, Inc. Announces Board Changes	Mar. 07
KalVista Pharmaceuticals, Inc. Announces Chief Executive Officer Changes	Mar. 07
Kalvista Pharmaceuticals Insider Sold Shares Worth $613,205, According to a Recent SEC Filing	Feb. 16
Kalvista Pharmaceuticals Insider Sold Shares Worth $598,661, According to a Recent SEC Filing	Feb. 16
Kalvista Pharmaceuticals Insider Sold Shares Worth $422,827, According to a Recent SEC Filing	Feb. 16
KalVista Pharmaceuticals to Present Phase 3 Sebetralstat Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting	Feb. 16
KalVista Pharmaceuticals' Phase 3 Trial of Sebetralstat to Treat Hereditary Angioedema Meets All Endpoints; Shares Rise	Feb. 13
KalVista meets main goals in late-stage trial for genetic disease	Feb. 13

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Carbylan Therapeutics Inc Nasdaq

Equities

US1413841073

Other languages

Filters